Autres langues Celltrion, Inc.

Actions

A068270

KR7068270008

Cours en clôture Korea S.E. Autres places de cotation 00:00:00 15/07/2024			Varia. 5j.	Varia. 1 janv.
188 700 ^KRW	-0,05 %		+1,56 %	-6,35 %

01/07	Les actions sud-coréennes augmentent grâce à des données solides ; les batteries et les valeurs biopharmaceutiques bondissent	RE
14/06	Celltrion, Inc. (KOSE:A068270) annonce un rachat d'actions pour 410 734 actions.	CI

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

S.Korean shares rise on robust data; battery, biopharma stocks jump	01/07
Preliminary Injunction Issued Against Samsung Bioepis In Aflibercept BPCIA Litigation	20/06
Celltrion Reveals Positive Phase III Results of Rheumatoid Arthritis Drug	17/06
Celltrion, Inc. announces an Equity Buyback for 410,734 shares.	14/06
Celltrion Showcases Promising Results in Phase III study for CT-P47, A Biosimilar Candidate of Roactemra® (Tocilizumab) in Patients with Rheumatoid Arthritis (RA) at EULAR 2024	14/06
Celltrion, Inc. authorizes a Buyback Plan.	14/06
MÄRKTE ASIEN/Meist freundlich - BYD-Rally nach EU-Strafzöllen	13/06
MÄRKTE ASIEN/Meist freundlich - Börsen folgen Vorgabe der Wall Street	13/06
Amgen Files BPCIA Complaint Against Celltrion Regarding Denosumab	10/06
European Biosimilar Regulatory Update	10/06
Celltrion's Avastin Biosimilar Gains 12% Market Share in Japan	07/06
AbbVie's tight grip on Humira market raises concerns about biosimilars	07/06
Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on April 17, 2024.	04/06
Celltrion, Inc.'s Equity Buyback announced on April 17, 2024, has closed with 436,047 shares, representing 0.21% for KRW 80,550.32 million.	31/05
Celltrion Receives European Commission Approval of Omlyclo® (CT-P39), the First and Only Omalizumab Biosimilar Approved in Europe	24/05
Celltrion - Reality TV Star, Mollie Pearce, Backs Campaign to Tackle Inequalities in Condition That Impacts Millions of People Globally	20/05
Celltrion USA announces two-year data for ZYMFENTRA(infliximab-dyyb) to be presented at Digestive Disease Week (DDW) 2024 Conference	20/05
Celltrion, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05
Court Cancels Injunction Hearings In Aflibercept BPCIA Litigation; Regeneron May Seek Temporary Restraining Orders	16/05
Celltrion's Q1 Attributable Profit Slumps 86%	10/05

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Celltrion, Inc.

Actions

A068270

KR7068270008

Autres langues

Filtres